Executive Summary
Rating: HOLD | ABT
This Abbott Laboratories stock analysis evaluates ABT’s investment case, currently rated HOLD. Abbott Laboratories is a diversified healthcare company with four operating segments spanning diagnostics, medical devices, nutrition, and established pharmaceuticals. The investment case is anchored by scale, recurring demand, and a broad global footprint, but the near-term debate centers on valuation and execution: the stock trades at 25.6x trailing earnings and 15.0x forward earnings, while Q1 2026 revenue declined 2.6% sequentially to $11.2B and EBIT fell to $1.6B from $2.5B in Q4 2025. The key risk is that margin pressure and acquisition-related financing needs could limit upside, while the main catalyst is sustained earnings recovery into 2026.
Investment Rating
Rating: HOLD
Abbott screens at 15.8x EV/EBITDA and 4.1x EV/Revenue, which is reasonable for a large-cap healthcare franchise but not compelling enough to justify a Buy on the current data. TTM operating margin was 13.5%, net margin was 13.9%, ROA was 5.6%, and ROE was 12.3%, indicating solid but not exceptional capital efficiency. The stock’s 0.6 beta supports relative defensiveness, but the valuation already reflects that stability.
Company Profile
Abbott Laboratories is an Illinois-based healthcare company founded in 1900 and listed on the New York Stock Exchange. It develops, manufactures, and sells products across four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Revenue is generated from branded generics outside the U.S., diagnostics and testing systems, pediatric and adult nutrition, and cardiovascular, diabetes, and neuromodulation devices sold globally. The company operates in more than 160 countries.
Economic Moat
Abbott’s moat is built on scale, regulatory complexity, and product integration rather than on a single dominant franchise. Its diagnostics and device platforms are embedded in hospital and laboratory workflows, which raises switching costs because replacement requires validation, training, and regulatory clearance. The company also benefits from a broad global commercial footprint and a portfolio of branded products that support repeat purchasing and customer retention.
Business Model
Abbott’s business model is diversified across recurring healthcare categories with different demand drivers. Diagnostics and medical devices provide exposure to installed-base replacement cycles, while nutrition and established pharmaceuticals add breadth and reduce dependence on any one product line. That mix helps smooth revenue, but it also means performance depends on execution across multiple regulatory and commercial channels.
Risk Factors
Exact Sciences acquisition financing risk is high severity: Abbott’s leverage profile already shows total debt of $34.1B and a total debt/equity ratio of 64.8%, so any incremental borrowing would tighten flexibility and could pressure refinancing terms. Cybersecurity risk is also high severity because a material systems breach could disrupt manufacturing, product availability, and customer service across a global operating base. Regulatory and product-safety enforcement is medium severity, as recalls, warning letters, or consent decrees can directly affect sales and reputation.
Management Discussion & Analysis
Management’s tone appears focused on preserving strategic flexibility while sustaining investment in the core franchise. The most relevant balance-sheet signal is the company’s current ratio of 1.4x and TTM operating cash flow of $9.5B, which indicate adequate near-term liquidity. Capital allocation remains centered on ongoing cash generation, with leverage manageable but not low enough to ignore if financing conditions tighten.
Recent Earnings
Q1 2026 showed slower momentum than the prior quarter. Revenue was $11.2B, down from $11.5B in Q4 2025, while EBIT fell to $1.6B from $2.5B and EBITDA declined to $2.4B from $3.3B. Net income was $1.1B versus $1.8B in Q4 2025, and diluted EPS was $0.6. The sequential decline in earnings outpaced the revenue pullback, suggesting some margin compression in the quarter.
Financial Analysis
Growth
ABT — Financial Growth (Quarterly, USD Mil)
| Metric | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|---|
| REVENUE (USD Mil) | 10,358.000 | 11,142.000 | 11,369.000 | 11,459.000 | 11,164.000 |
| EBIT (USD Mil) | 1,909.000 | 2,271.000 | 2,301.000 | 2,478.000 | 1,623.000 |
| EBITDA (USD Mil) | 2,665.000 | 3,048.000 | 3,092.000 | 3,270.000 | 2,426.000 |
| NET INCOME (USD Mil) | 1,325.000 | 1,779.000 | 1,644.000 | 1,776.000 | 1,077.000 |
| DILUTED EPS | 0.760 | 1.010 | 0.940 | 1.010 | 0.610 |
Source: Yahoo Finance — Quarterly Financial Statements
Abbott’s quarterly revenue increased from $10.4B in Q1 2025 to $11.5B in Q4 2025 before easing to $11.2B in Q1 2026. Over the same period, EBIT rose from $1.9B to $2.5B and then fell to $1.6B, while EBITDA moved from $2.7B to $3.3B and then to $2.4B. Net income followed the same pattern, rising from $1.3B to $1.8B before dropping to $1.1B in Q1 2026.
Profitability
ABT — Profitability (TTM)
| Metric | TTM |
|---|---|
| Operating Margin (TTM) | 13.5% |
| Net Margin (TTM) | 13.9% |
| Return on Assets (TTM) | 5.6% |
| Return on Equity (TTM) | 12.3% |
Source: Yahoo Finance — Trailing Twelve Months (TTM)
TTM operating margin was 13.5%, net margin was 13.9%, ROA was 5.6%, and ROE was 12.3%. Those figures point to a profitable business with respectable returns, though not at the level of the highest-quality healthcare peers. The key question is whether margin stability can be maintained as growth moderates.
Valuation
ABT — Valuation Multiples
| Metric | Value |
|---|---|
| Market Cap (USD Mil) | 158,888.198 |
| Enterprise Value (USD Mil) | 185,115.017 |
| Trailing P/E | 25.552 |
| Forward P/E | 15.048 |
| Price/Sales (TTM) | 3.520 |
| Price/Book (mrq) | 3.052 |
| EV/Revenue | 4.101 |
| EV/EBITDA | 15.763 |
| Beta (5Y Monthly) | 0.620 |
Source: Yahoo Finance
Abbott trades at 25.6x trailing P/E, 15.0x forward P/E, 3.5x price/sales, 3.1x price/book, 4.1x EV/revenue, and 15.8x EV/EBITDA. Market capitalization is $158.9B and enterprise value is $185.1B. The valuation is consistent with a mature, defensive healthcare franchise, but it does not leave much room for disappointment in earnings execution.
Leverage
ABT — Leverage & Coverage (Quarterly)
| Metric | Value |
|---|---|
| Total Debt/Equity % (mrq) | 6,477.3% |
| Current Ratio (mrq) | 1.388 |
| Total Debt (mrq, USD Mil) | 34,136.001 |
| Operating Cash Flow (TTM, USD Mil) | 9,464.001 |
| Levered Free Cash Flow (TTM, USD Mil) | 6,341.125 |
Source: Yahoo Finance — Quarterly Financial Statements
Abbott’s total debt/equity ratio was 64.8% and its current ratio was 1.4x. Total debt was $34.1B, while TTM operating cash flow was $9.5B and levered free cash flow was $6.3B. That cash generation provides meaningful support for the balance sheet, but leverage is high enough that financing discipline remains important.
Comparable Analysis
Abbott’s 7.8% revenue growth was below ABBV’s 12.4% and JNJ’s 9.9%, but above BDX’s 5.2% and BAX’s 2.9%. On profitability, Abbott’s 13.5% operating margin and 13.9% net margin sit below JNJ’s 27.4% and 21.8%, and below ABBV’s 32.2% operating margin, but ahead of BAX’s 6.0% operating margin and negative 9.7% net margin. On leverage, Abbott’s 64.8% debt/equity is below BAX’s 161.0% and close to JNJ’s 67.7%, while its current ratio of 1.4x is stronger than JNJ’s 1.0x and BDX’s 0.9x.
Growth
| Company | Revenue TTM (USD Mil) | Revenue Growth YoY % | EBITDA TTM (USD Mil) | Diluted EPS TTM |
|---|---|---|---|---|
| ABT | 45,134.000 | 7.8% | 11,744.000 | 3.570 |
| JNJ | 96,362.000 | 9.9% | 34,325.000 | 8.640 |
| ABBV | 62,819.000 | 12.4% | 29,915.000 | 2.030 |
| MDT | 36,364.000 | 9.9% | 10,081.000 | 3.730 |
| BAX | 11,320.000 | 2.9% | 1,909.000 | -1.910 |
| BDX | 22,227.000 | 5.2% | 6,157.000 | 5.730 |
Valuation
| Company | Trailing P/E | Forward P/E | EV/Revenue | EV/EBITDA | Price/Sales (TTM) | Price/Book (mrq) | Market Cap (USD Mil) | Enterprise Value (USD Mil) | Beta (5Y Monthly) |
|---|---|---|---|---|---|---|---|---|---|
| ABT | 25.552 | 15.048 | 4.101 | 15.763 | 3.520 | 3.052 | 158,888.200 | 185,115.020 | 0.620 |
| JNJ | 27.268 | 18.525 | 6.141 | 17.241 | 5.885 | 6.984 | 567,128.290 | 591,795.520 | 0.256 |
| ABBV | 110.808 | 13.838 | 7.286 | 15.299 | 6.326 | -59.713 | 397,422.400 | 457,683.470 | 0.309 |
| MDT | 21.952 | 12.773 | 3.396 | 12.250 | 2.891 | 2.145 | 105,124.500 | 123,495.680 | 0.597 |
| BAX | — | 9.720 | 1.553 | 9.209 | 0.894 | 1.675 | 10,122.790 | 17,579.860 | 0.642 |
| BDX | 26.284 | 11.241 | 2.600 | 9.386 | 1.867 | 1.720 | 41,499.140 | 57,791.310 | 0.278 |
Profitability
| Company | Operating Margin (TTM) | Net Margin (TTM) | Return on Assets (TTM) | Return on Equity (TTM) |
|---|---|---|---|---|
| ABT | 13.5% | 13.9% | 5.6% | 12.3% |
| JNJ | 27.4% | 21.8% | 8.4% | 26.4% |
| ABBV | 32.2% | 5.8% | 10.0% | — |
| MDT | 21.3% | 13.2% | — | 9.9% |
| BAX | 6.0% | -9.7% | 2.8% | -15.0% |
| BDX | 14.7% | 5.1% | 4.4% | 6.7% |
Leverage
| Company | Total Debt/Equity % (mrq) | Current Ratio (mrq) | Total Debt (mrq, USD Mil) | Operating Cash Flow TTM (USD Mil) | Free Cash Flow TTM (USD Mil) |
|---|---|---|---|---|---|
| ABT | 6,477.3% | 1.388 | 34,136.000 | 9,464.000 | 6,341.130 |
| JNJ | 6,773.0% | 1.025 | 54,987.000 | 22,870.000 | 12,511.380 |
| ABBV | — | 0.796 | 72,912.000 | 21,224.000 | 20,811.620 |
| MDT | 5,706.0% | — | 28,071.000 | 7,330.000 | — |
| BAX | 16,102.1% | 1.854 | 9,687.000 | 1,251.000 | 900.880 |
| BDX | 7,159.9% | 0.942 | 17,279.000 | 3,828.000 | 4,531.250 |
Returns
| Company | Return on Equity (TTM) | Return on Assets (TTM) |
|---|---|---|
| ABT | 12.3% | 5.6% |
| JNJ | 26.4% | 8.4% |
| ABBV | — | 10.0% |
| MDT | 9.9% | — |
| BAX | -15.0% | 2.8% |
| BDX | 6.7% | 4.4% |
Source: Yahoo Finance
Conclusion
Abbott offers a defensible healthcare franchise with solid cash generation, moderate leverage, and a valuation that is fair rather than cheap. The investment case depends on whether management can sustain earnings growth while keeping the balance sheet stable and preserving margin discipline. With TTM ROE at 12.3% and levered free cash flow at $6.3B, the company has enough financial capacity to absorb volatility, but the current setup supports a hold rather than an aggressive buy.
Data sourced from Yahoo Finance. Not investment advice.
Leave a Reply